News

The shares were issued at a price of $0.95 per share, with each investor also receiving warrants to purchase the number of shares of class A common stock

The investigational new drug (IND) application is for a Phase I safety and immunogenicity study of this influenza vaccine in healthy volunteers. The filing initiates a 30-day review

According to the company, Pass Rx employs patented sensor technologies to generate a unique spectral fingerprint and image data of the size, color and shape of the drug.

With the extension of the agreement, Healthways and the Premera companies will continue their innovative care support program that links customizable disease management solutions with faster and more

Ron Howell, CEO and president of HST Global retained Ebitda Capital, said: “Through the use of the Ebitda Capital resources we at HST Global can focus on the

Neurologix and Diamyd have signed the license agreement in August 2006. It is a running agreement with milestone payments and royalty on sales. Elisabeth Lindner, president and CEO

ImmunoVEX HSV2 is a novel live-attenuated vaccine which has been rationally designed to remove the genes that allow herpes virus to avoid the immune system. This should allow

The trial is a double-blind, placebo-controlled, dose-escalating clinical study evaluating the safety and efficacy of the company’s topical drug candidate, RGN-137, in 72 patients with pressure ulcers who

Under the merger agreement, Lilly will acquire all of the outstanding shares of SGX common stock at a price of $3 per share. All other closing conditions have